Cochlear vs Pro Medicus: When Quality Meets Extreme Overvaluation
Cochlear and Pro Medicus are two of the highest-quality businesses on the ASX, both overvalued by 60%+, and both just reported disappointing H1 results. The comparison isolates the quality premium trap from two different angles.
Cochlear and Pro Medicus are two of the highest-quality businesses on the ASX, and both are among the most overvalued stocks in our coverage. COH scores 8.0/10 on our quality framework with 60%+ global market share in cochlear implants. PME scores 8.4/10 with 73% EBIT margins selling cloud-native imaging software to the world's largest hospitals. Both just reported disappointing H1 FY26 results, and both trade at roughly three times our probability-weighted fair values.
The comparison is instructive because it isolates the same phenomenon from different angles: the market prices quality at extreme premiums, then punishes even the smallest earnings deviation. COH fell on flat revenue and an 11% EBIT decline. PME fell 14.9% on a 2% revenue miss. The businesses are excellent. The prices are not.
The Comparison
| Metric | COH | PME |
|---|---|---|
| Rating | SELL | SELL |
| Price | A$300 | A$138.46 |
| Fair Value | A$110.09 | A$54.00 |
| Gap | -63% (overvalued) | -61% (overvalued) |
| Quality Score | 8.0 / 10 | 8.4 / 10 |
| Revenue (H1 FY26) | A$1,176M | Missed by 2% |
| Revenue Growth (H1) | +1% reported (-2% CC) | Below consensus |
| EBIT Margin | 22% (down from 25%) | 73% |
| Gross Margin | 73% (down from 75%) | ~100% |
| ROIC | 22.5% | Very high (asset-light) |
| Moat Type | Physical device + switching cost | Software platform + switching cost |
| TAM Penetration | <5% adult (cochlear implants) | Early innings (US hospitals) |
| H1 FY26 Reaction | Weak, margin compression | -14.9% sell-off |
| Contracted Revenue | Lifetime upgrade cycle | A$1B+ backlog, 100% renewals |
Where Cochlear Wins
Cochlear's moat is physical. A cochlear implant is surgically embedded in the skull, and once implanted, the patient is a Cochlear customer for life. Upgrades to external sound processors happen every 5-7 years, creating an annuity revenue stream that no software migration or platform switch can replicate. The switching cost is measured in surgery, not in IT procurement cycles.
The global market share of 60%+ reflects four decades of R&D compounding into the deepest clinical evidence base in the industry. The Nucleus Nexa system, launched in June 2025 as the first smart cochlear implant with upgradeable firmware, has already reached 80% of new implant mix by December 2025. This is not a business losing share or facing disruption.
The addressable market is the strongest long-term argument. Less than 5% of adults with severe-to-profound hearing loss globally have a cochlear implant. Growing evidence linking untreated hearing loss to cognitive decline is expanding referral pathways. At 27,016 CI units sold in H1 FY26 (+6%, with exit-rate momentum at +10%), COH is barely scratching the surface of a TAM that could support decades of high-single-digit unit growth.
Where Pro Medicus Wins
Pro Medicus wins on economics. A 73% EBIT margin with near-zero marginal cost per additional customer is the kind of business model that generates extreme returns on capital without requiring factories, warehouses, or physical distribution. Every new hospital contract flows almost entirely to the bottom line.
The competitive moat is different but equally durable. PME's Visage platform is the only true cloud-native enterprise imaging solution operating at scale in the US hospital system, serving 11 of the top 20 US hospitals. Radiology imaging is deeply embedded in clinical workflows, and the cost of switching (data migration, clinician retraining, integration with electronic health records) makes contract renewals near-automatic. The 100% renewal rate and A$1 billion-plus contracted backlog provide revenue visibility that most SaaS companies cannot match.
The contracted backlog also provides a structural advantage in the current environment. While COH faces short-term headwinds from emerging market mix dilution (gross margins compressing from 75% to 73%), PME's existing contracts lock in pricing regardless of macro conditions. The revenue miss was about the timing of new contract wins, not attrition from existing customers.
The Quality Premium Trap
Both companies illustrate the central finding from our quality premium analysis: the market systematically overprices quality businesses and then amplifies volatility around earnings events.
At A$300, COH needs sustained 10%+ CI unit growth at peak margins for 15+ years. At A$138, PME needs sustained 30%+ revenue growth at peak margins for 15+ years. Both assumptions embed a near-zero probability of any operational setback, competitive disruption, or margin normalisation. When even a single quarter deviates from this trajectory (as both just experienced), the sell-off is disproportionate to the fundamental impact.
The difference is in the nature of the overvaluation. COH's gap is driven by a market willing to pay 22x EBIT for a medical device business that generated flat revenue growth in H1 and is navigating a product transition (Nexa replacing legacy systems). PME's gap is driven by a market willing to pay 156% above DCF fair value for a software platform with no immediate competitive threat but a growth rate that mathematically must decelerate.
Both stocks have the same vulnerability: the option value embedded in the premium is fragile. A structural change in growth assumptions (not a single bad quarter, but a sustained deceleration) would collapse the premium because there is no fundamental floor near the current price. COH's floor is roughly A$92 (bear case), which is 69% below the current price. PME's floor is roughly A$35 (bear case), which is 75% below. The asymmetry is unfavourable for both.
Which Overvaluation Is More Defensible?
If the question is which stock could sustain its premium longer, the answer favours COH.
COH's <5% TAM penetration provides a longer runway for unit growth than any comparable metric at PME. The razor-razorblade model (implant plus lifetime upgrades) creates a compounding installed base that grows regardless of new sales in any given quarter. Even if CI unit growth decelerates from 10% to 6%, the services revenue from the existing installed base provides a floor.
PME's growth, by contrast, is entirely dependent on winning new hospital contracts. The A$1 billion backlog is impressive, but once the US top-20 hospital system is substantially penetrated, the next wave of growth requires either international expansion (uncertain) or adjacent verticals (unproven). The margin profile assumes no competitive entry from well-funded platform players with adjacent hospital relationships.
Neither argument justifies the current prices. But if forced to allocate between the two at current levels, COH's physical moat and installed base provide a more defensible long-term position, despite the near-identical overvaluation gap.
Bottom Line
Cochlear and Pro Medicus are both exceptional businesses that no fundamental analyst would dispute. COH has the deeper physical moat and the longer TAM runway. PME has the better unit economics and the cleaner revenue model. Both are overvalued by roughly the same margin (63% and 61% respectively), both carry the same vulnerability to the quality premium trap, and neither offers attractive risk-reward from current prices.
The pattern across our coverage is consistent: quality scores above 8.0 correlate strongly with overvaluation above 50%. The market is paying for certainty in businesses where the fundamentals are genuinely excellent, and the premium it assigns leaves no margin for error. Both stocks are worth monitoring for entry points, with COH becoming interesting below A$150 and PME below A$75, but at current levels the risk-reward is asymmetrically negative for both.
Analysis generated by the Alpha Insights AI research pipeline. All fair values are point estimates subject to model uncertainty. This is not financial advice. Do your own research before making investment decisions.